Metagenomi Inc. Common St...

AI Score

0

Unlock

2.77
-0.14 (-4.81%)
At close: Jan 14, 2025, 3:59 PM
2.75
-0.53%
After-hours Jan 14, 2025, 06:05 PM EST
undefined%
Bid 2.75
Market Cap 103.48M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.24
PE Ratio (ttm) -1.23
Forward PE n/a
Analyst Buy
Ask 2.81
Volume 479,835
Avg. Volume (20D) 1,935,972
Open 2.97
Previous Close 2.91
Day's Range 2.67 - 2.97
52-Week Range 1.61 - 12.74
Beta undefined

About MGX

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and lice...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 6, 2006
Employees 236
Stock Exchange NASDAQ
Ticker Symbol MGX

Analyst Forecast

According to 7 analyst ratings, the average rating for MGX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 478.66% from the latest price.

Buy 85.71%
Hold 14.29%
Sell 0.00%
Stock Forecasts
8 months ago · Source
-12.36%
Metagenomi shares are trading lower after Moderna ... Unlock content with Pro Subscription